July 30, 2019 — Boston, MA


Topic: The New Normal: US + Chinese BioPharma to Drive the Next Generation of Innovative Medicines

Tuesday, July 30, 2019         
The Colonnade Hotel
Boston, MA

About Ian Tzeng
Ian Tzeng, a Managing Director and Partner in L.E.K.’s Boston office, joined the company in 1998 with experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He focuses on healthcare and life sciences, including pharmaceuticals, vaccines and medical devices. He leads L.E.K.’s Pharmaceutical Contract Services practice, including CROs, CDMOs, supply chain and distribution, commercial, medical, and market access services. Other areas of deep experience include rare diseases, biodefense, biosimilars and generics, and consumer-directed healthcare.

Additionally, Ian has extensive consulting and board experience with nonprofit organizations in education, arts, LGBT advocacy and public service. He received a Bachelor of Arts degree, magna cum laude, in chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.

The inaugural CHINATRIALS+US Summit launches amidst the recent boom of new innovative Chinese biotechs and updated CFDA regulations that enable international biopharmas to more easily bring their medicines to China.

The Summit will bring together 100+ clinical development leaders from Chinese innovative biotechs interested in launching clinical trials in the US and US biotechs interested in entering the China market.

Discussion topics will focus on the key considerations needed to develop an effective global development strategy that includes both the US and China markets. We hope the synergies of bringing these two important groups together will foster new opportunities into partnerships and collaboration for parallel drug development in the US and China.

About L.E.K. Consulting
L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries — including the largest private- and public-sector organizations, private equity firms, and emerging entrepreneurial businesses. Founded in 1983, L.E.K. employs more than 1,400 professionals across the Americas, Asia-Pacific and Europe. For more information, go to www.lek.com.